Physician profile
Mark Himes
NPI 1043571458
$4,348.90
in general payments reported to CMS, 2019-2025
29 companies · $556 in 2025
The $556 reported for 2025 was more than what 84% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $640 · 2021: $939 · 2022: $533 · 2023: $645 · 2024: $587 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $687.61 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.15 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $421.83 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astellas Pharma US INC | $329.32 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $311.23 | 2019-2023 | Xarelto |
| Abbvie INC. | $251.87 | 2021-2025 | |
| Amgen INC. | $241.25 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $237.70 | 2019-2025 | |
| Novo Nordisk INC | $201.09 | 2021-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $161.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $132.42 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $107.58 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.65 | 2022-2025 | Xifaxan, Trulance |
| Insulet Corporation | $80.46 | 2025 | Omnipod |
| Myriad Women'S Health, INC. | $61.58 | 2023 | Myrisk |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $60.57 | 2021 | |
| Boston Scientific Corporation | $58.82 | 2023-2024 | Intracept |
| Mylan Specialty L.P. | $57.87 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $53.19 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $50.36 | 2023 | |
| Lundbeck LLC | $46.21 | 2021-2023 | Vyepti |
| Exact Sciences Corporation | $39.29 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $33.47 | 2023 | |
| Gilead Sciences, INC. | $29.47 | 2019-2020 | |
| Allergan, INC. | $27.34 | 2020 | |
| Pacira Therapeutics, INC. | $26.54 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $20.70 | 2024 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2025 | |
| Medtronic, INC. | $13.79 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Himes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.